Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.11, $0.13 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $130.9 million versus the consensus estimate of $129.2 million.

“The approval of Qelbree provides pediatric patients living with ADHD a therapy with proven efficacy and a tolerable safety profile, and that is not a controlled substance,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals. “Our Qelbree commercial launch activities are ongoing and include engagement with both physicians and patient groups who have expressed great interest in this unique new alternative for the treatment of ADHD.”

GUIDANCE:

Supernus Pharma sees FY2021 revenue of $550-580 million, versus the consensus of $569.54 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.